Jaguar Health's Losses Widen Amid Rising Expenses, Cash Dwindles

TL;DR

**JAGX is burning cash and widening losses, making it a risky bet for short-term gains.**

AI Summary

Jaguar Health, Inc. reported a net loss of $10.56 million for the three months ended June 30, 2025, an increase from a net loss of $9.63 million in the same period of 2024. For the six months ended June 30, 2025, the net loss widened to $21.16 million from $19.00 million in 2024. Total revenue, net, saw a slight increase to $2.98 million for the three months ended June 30, 2025, up from $2.72 million in 2024, and to $5.19 million for the six months ended June 30, 2025, compared to $5.07 million in 2024. Operating expenses rose significantly, reaching $10.99 million for the three-month period in 2025, up from $9.92 million in 2024, and $22.62 million for the six-month period in 2025, compared to $20.48 million in 2024. The company experienced a loss on extinguishment of debt of $1.82 million in the first six months of 2025, contrasting with a gain of $1.25 million in the prior year. Cash decreased substantially from $8.00 million at December 31, 2024, to $2.21 million at June 30, 2025, primarily due to $13.51 million in cash used in operating activities. Strategic financing activities included proceeds of $3.25 million from an At the Market offering and $3.45 million from Convertible Notes in the first six months of 2025.

Why It Matters

Jaguar Health's widening net losses and significant cash burn are critical for investors, signaling ongoing financial instability and potential dilution. The company's reliance on equity and debt financing, such as the $3.25 million from an At the Market offering and $3.45 million from Convertible Notes, indicates a need for continuous capital raises, which could further depress shareholder value. For employees and customers, sustained losses could impact product development and operational stability. In a competitive pharmaceutical market, Jaguar Health's struggle to achieve profitability puts it at a disadvantage, making it harder to invest in R&D and market penetration.

Risk Assessment

Risk Level: high — Jaguar Health reported a net loss of $21.16 million for the six months ended June 30, 2025, an increase from $19.00 million in the prior year, and cash decreased from $8.00 million to $2.21 million in the same period. The company used $13.51 million in cash from operating activities, indicating a high burn rate and significant liquidity concerns.

Analyst Insight

Investors should exercise extreme caution and consider divesting, given the widening losses and substantial cash burn. The company's reliance on dilutive financing methods suggests continued pressure on share price, making it unsuitable for risk-averse portfolios.

Financial Highlights

debt To Equity

N/A

revenue

$5.19M

operating Margin

N/A

total Assets

$48.27M

total Debt

$41.39M

net Income

-$21.16M

eps

N/A

gross Margin

N/A

cash Position

$2.21M

revenue Growth

+2.4%

Key Numbers

• $21.16M — Net Loss (Increased from $19.00M in H1 2024, indicating widening losses.)
• $2.21M — Cash (Decreased from $8.00M at Dec 31, 2024, highlighting liquidity concerns.)
• $13.51M — Cash Used in Operating Activities (Significant cash burn for H1 2025, up from $15.22M in H1 2024.)
• $5.19M — Total Revenue, Net (Slight increase from $5.07M in H1 2024, showing minimal top-line growth.)
• $22.62M — Total Operating Expenses (Increased from $20.48M in H1 2024, contributing to higher losses.)
• $1.82M — Loss on Extinguishment of Debt (A significant loss in H1 2025, compared to a gain of $1.25M in H1 2024.)
• $2.41M — Changes in Fair Value of Financial Instruments (A loss in H1 2025, compared to a loss of $3.83M in H1 2024.)
• 1,530,128 — Voting Common Stock Outstanding (Increased from 528,440 at Dec 31, 2024, indicating significant dilution.)

Key Players & Entities

• Jaguar Health, Inc. (company) — registrant
• Streeterville (company) — preferred stock and note holder
• Iliad (company) — preferred stock and note holder
• Irving (company) — note holder
• $10.56 million (dollar_amount) — net loss for Q2 2025
• $21.16 million (dollar_amount) — net loss for H1 2025
• $2.21 million (dollar_amount) — cash balance as of June 30, 2025
• $8.00 million (dollar_amount) — cash balance as of December 31, 2024
• $13.51 million (dollar_amount) — cash used in operating activities for H1 2025
• $3.25 million (dollar_amount) — proceeds from At the Market offering in H1 2025

FAQ

Risk Factors

• Liquidity and Going Concern [high — financial]: The company has a history of net losses and negative cash flows from operations, with a net loss of $21.16 million for the six months ended June 30, 2025. Cash decreased from $8.00 million to $2.21 million during the same period, primarily due to $13.51 million used in operating activities. This raises substantial doubt about the company's ability to continue as a going concern.
• Debt Obligations and Refinancing Risk [high — financial]: Total liabilities stand at $41.39 million as of June 30, 2025, with significant current liabilities of $29.22 million, including $18.57 million in notes payable. The company incurred a $1.82 million loss on extinguishment of debt in H1 2025, indicating potential challenges in managing its debt structure and refinancing obligations.
• Dilution from Stock Issuances [medium — financial]: The number of voting common stock outstanding increased significantly from 528,440 at December 31, 2024, to 1,530,128 at June 30, 2025. This substantial dilution, likely driven by financing activities like the At the Market offering and Convertible Notes, can negatively impact existing shareholders' value.
• Increasing Operating Expenses [medium — operational]: Total operating expenses rose to $22.62 million for the six months ended June 30, 2025, up from $20.48 million in the prior year. This increase in expenses, outpacing revenue growth, contributes to the widening net loss and puts pressure on profitability.
• Product Development and Regulatory Approval [high — regulatory]: As a pharmaceutical company, Jaguar Health is subject to stringent regulatory requirements for drug development and approval. Delays or failures in obtaining regulatory approvals for its products can significantly impact revenue generation and market access.
• Competition in Pharmaceutical Market [medium — market]: The pharmaceutical industry is highly competitive, with established players and emerging biotechs vying for market share. Jaguar Health faces competition for its existing and pipeline products, which could affect pricing power and sales volumes.

Industry Context

Jaguar Health operates in the highly competitive and regulated pharmaceutical and biotechnology sector, focusing on gastrointestinal health. The industry is characterized by long development cycles, significant R&D investment, and the need for extensive clinical trials and regulatory approvals. Key trends include the increasing demand for specialized therapeutics and the ongoing consolidation within the sector.

Regulatory Implications

As a biopharmaceutical company, Jaguar Health is subject to rigorous oversight by regulatory bodies like the FDA. Compliance with manufacturing standards, clinical trial protocols, and marketing regulations is critical. Any missteps or delays in regulatory processes can have severe financial and operational consequences.

What Investors Should Do

1. Monitor cash burn rate closely: With cash decreasing significantly and high operating cash outflows, investors should track the company's ability to manage its liquidity.
2. Evaluate dilution impact: The substantial increase in outstanding shares warrants careful consideration of the impact on per-share value and ownership percentage.
3. Assess debt management strategy: Investors should scrutinize the company's plans for managing its significant debt load and refinancing obligations.
4. Analyze revenue drivers: Given the minimal revenue growth, understanding the catalysts for future top-line expansion is crucial.
5. Review risk factors: Pay close attention to the company's disclosures regarding going concern, debt, and regulatory risks.

Glossary

At the Market offering

A type of public offering where a company sells its stock directly to the public over a period of time at prevailing market prices. (Indicates a method of capital raising that can lead to stock dilution.)

Convertible Notes

Debt instruments that can be converted into a predetermined amount of the issuer's equity at certain times. (Represents a form of financing that can convert to equity, potentially causing dilution.)

Loss on Extinguishment of Debt

A loss recognized when a company repays or retires debt before its scheduled maturity date, often due to unfavorable market conditions or refinancing costs. (Highlights costs associated with debt management and potential financial distress.)

Fair Value Option

An accounting election that allows certain financial instruments to be reported at their fair value, with changes in value recognized in earnings. (Affects the reported value of certain notes payable, introducing volatility in earnings.)

Going Concern

An accounting assumption that a company will continue to operate for the foreseeable future. If doubt exists, it must be disclosed. (The company's financial condition raises substantial doubt about its ability to continue as a going concern.)

Year-Over-Year Comparison

Compared to the prior year, Jaguar Health's financial performance has weakened. Net losses have widened in both the three-month and six-month periods ended June 30, 2025. While total revenue saw a slight increase, operating expenses grew at a faster pace, contributing to the increased losses. A significant shift from a gain to a loss on extinguishment of debt also negatively impacted profitability. The company's cash position has deteriorated substantially, underscoring increased financial pressure.

Key Financial Figures

• $0.0001 — h registered: Common stock, Par Value $0.0001 Per Share JAGX The NASDAQ Capital M

Filing Documents

• jagx-20250630.htm (10-Q) — 5590KB
• jagx-ex31_1.htm (EX-31.1) — 17KB
• jagx-ex31_2.htm (EX-31.2) — 17KB
• jagx-ex32_1.htm (EX-32.1) — 10KB
• jagx-ex32_2.htm (EX-32.2) — 10KB
• 0000950170-25-108393.txt ( ) — 22588KB
• jagx-20250630.xsd (EX-101.SCH) — 2420KB
• jagx-20250630_htm.xml (XML) — 5175KB

— FINANCIAL INFORMATION

PART I. — FINANCIAL INFORMATION 1

Condensed Consolidated Financial Statements

Item 1. Condensed Consolidated Financial Statements 1 Condensed Consolidated Balance Sheets 1 Condensed Consolidated Statements of Operations 2 Condensed Consolidated Statements of Comprehensive Losses 3 Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity 4 Condensed Consolidated Statements of Cash Flows 8 Notes to Condensed Consolidated Financial Statements 10

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 53

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 70

Controls and Procedures

Item 4. Controls and Procedures 70

— OTHER INFORMATION

PART II. — OTHER INFORMATION 71

Legal Proceedings

Item 1. Legal Proceedings 71

Risk Factors

Item 1A. Risk Factors 71

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 72

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 73

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 73

Other Information

Item 5. Other Information 73

Exhibits

Item 6. Exhibits 74 SIGNATURE 75 Table of Contents

— FINANCIAL INF ORMATION

PART I. — FINANCIAL INF ORMATION

Condensed Consolidated Financial Statements

Item 1. Condensed Consolidated Financial Statements JAGUAR HEALTH, INC. CONDENSED CONSOLIDATED BALANCE SHEETS June 30, December 31, (In thousands, except share and per share data) 2025 2024 (unaudited) Assets Current assets: Cash $ 2,207 $ 8,002 Accounts receivable, net 1,173 1,527 Other receivable 143 120 Inventory 10,719 10,345 Prepaid expenses and other current assets 13,661 12,204 Total current assets 27,903 32,198 Property and equipment, net 441 464 Operating lease - right-of-use asset 1,138 936 Intangible assets, net 17,545 18,479 Other assets 1,241 1,348 Total assets $ 48,268 $ 53,425 Liabilities, Redeemable preferred stock, and Stockholders' equity Current liabilities: Accounts payable $ 6,617 $ 5,286 Accrued liabilities 3,603 1,911 Deferred revenue 170 170 Operating lease liability, current 256 299 Notes payable, net of discount (includes note designated at Fair Value Option amounting to $ 18.1 million as of June 30, 2025, and $ 11.9 million as of December 31, 2024, respectively) 18,572 12,038 Total current liabilities 29,218 19,704 Operating lease liability, net of current portion 960 686 Deferred revenue, net of current portion 468 553 Notes payable, net of discount, net of current portion (includes notes designated at Fair Value Option amounting to $ 10.7 million as of June 30, 2025, and $ 21.7 million as of December 31, 2024, respectively) 10,742 23,503 Total liabilities 41,388 44,446 Commitments and contingencies (See Note 6) Redeemable preferred stock: $ 0.0001 par value; 179 shares designated from 10,000,000 preferred stock authorized at June 30, 2025, and December 31, 2024; 99 shares issued and outstanding at June 30, 2025 and December 31, 2024 — 2,485 Stockholders' equity Series G convertible preferred stock: $ 0.0001 par value; 137 shares designated from 10,000,000 preferred s